dihydroergotoxine and Asthma

dihydroergotoxine has been researched along with Asthma* in 4 studies

Reviews

2 review(s) available for dihydroergotoxine and Asthma

Article	Year
The radioligand binding approach in the study of lymphocytic adrenoceptors and the constitutional basis of atopy. The Journal of allergy and clinical immunology, 1980, Volume: 65, Issue:1 Topics: Adenosine Monophosphate; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Airway Obstruction; Animals; Anura; Asthma; B-Lymphocytes; Binding Sites; Catecholamines; Cell Membrane; Dermatitis, Atopic; Dihydroalprenolol; Dihydroergotoxine; Humans; Hypersensitivity, Immediate; Lymphocytes; Radioligand Assay; T-Lymphocytes	1980
Changes in adrenoceptor densities in membranes of lung tissue and lymphocytes from patients with atopic disease. Annals of the New York Academy of Sciences, 1979, Volume: 332 Topics: Airway Obstruction; Asthma; Bronchodilator Agents; Cell Membrane; Cyclic AMP; Dihydroalprenolol; Dihydroergotoxine; Humans; Hypersensitivity, Immediate; Lung; Lymphocytes; Membranes; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta	1979

Article

Year

The radioligand binding approach in the study of lymphocytic adrenoceptors and the constitutional basis of atopy.

The Journal of allergy and clinical immunology, 1980, Volume: 65, Issue:1

Topics: Adenosine Monophosphate; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Airway Obstruction; Animals; Anura; Asthma; B-Lymphocytes; Binding Sites; Catecholamines; Cell Membrane; Dermatitis, Atopic; Dihydroalprenolol; Dihydroergotoxine; Humans; Hypersensitivity, Immediate; Lymphocytes; Radioligand Assay; T-Lymphocytes

1980

Changes in adrenoceptor densities in membranes of lung tissue and lymphocytes from patients with atopic disease.

Annals of the New York Academy of Sciences, 1979, Volume: 332

Topics: Airway Obstruction; Asthma; Bronchodilator Agents; Cell Membrane; Cyclic AMP; Dihydroalprenolol; Dihydroergotoxine; Humans; Hypersensitivity, Immediate; Lung; Lymphocytes; Membranes; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta

1979

Other Studies

2 other study(ies) available for dihydroergotoxine and Asthma

Article	Year
Effects of histamine on alpha adrenergic receptor expression on the lymphocytes of normal and asthmatic subjects. Annals of allergy, 1990, Volume: 65, Issue:1 Low levels of [3H]-dihydroergocryptine (DHE) (alpha adrenergic receptor) binding to peripheral blood mononuclear leukocytes from asthmatic subjects were significantly increased following incubation with histamine. In contrast, [3H]-DHE binding was undetectable both before and after histamine incubation using cells from nonasthmatic subjects. The change in binding showed a biphasic dose dependence on histamine and was not associated with changes in DHA (beta-2 receptor) or yohimbine (alpha-2 receptor) binding. The induction of alpha adrenergic receptors by the ubiquitous inflammatory mediator histamine may help explain the alpha adrenergic hyperresponsiveness seen in asthmatic patients. Topics: Asthma; Dihydroalprenolol; Dihydroergotoxine; Dose-Response Relationship, Drug; Histamine; Humans; Monocytes; Prazosin; Receptors, Adrenergic, alpha; Reference Values; Yohimbine	1990
The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine'). Pharmatherapeutica, 1980, Volume: 2, Issue:5 A study was carried out in 40 patients with bronchial asthma to assess the therapeutic effect of co-dergocrine ('Hydergine'), an alpha-adrenergic receptor blocking agent, when added to their standard treatment with a beta-adrenergic receptor stimulant and aminophylline. Co-dergocrine administration (3 to 6 mg per day) brought about marked improvement in 25% and an improvement in 55% of the patients. The results suggest that co-dergocrine could be a useful drug when combined with other bronchodilators in the treatment of bronchial asthma. Topics: Adult; Aged; Asthma; Bronchodilator Agents; Dihydroergotoxine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged	1980

Article

Year

Effects of histamine on alpha adrenergic receptor expression on the lymphocytes of normal and asthmatic subjects.

Annals of allergy, 1990, Volume: 65, Issue:1

Low levels of [3H]-dihydroergocryptine (DHE) (alpha adrenergic receptor) binding to peripheral blood mononuclear leukocytes from asthmatic subjects were significantly increased following incubation with histamine. In contrast, [3H]-DHE binding was undetectable both before and after histamine incubation using cells from nonasthmatic subjects. The change in binding showed a biphasic dose dependence on histamine and was not associated with changes in DHA (beta-2 receptor) or yohimbine (alpha-2 receptor) binding. The induction of alpha adrenergic receptors by the ubiquitous inflammatory mediator histamine may help explain the alpha adrenergic hyperresponsiveness seen in asthmatic patients.

Topics: Asthma; Dihydroalprenolol; Dihydroergotoxine; Dose-Response Relationship, Drug; Histamine; Humans; Monocytes; Prazosin; Receptors, Adrenergic, alpha; Reference Values; Yohimbine

1990

The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine').

Pharmatherapeutica, 1980, Volume: 2, Issue:5

A study was carried out in 40 patients with bronchial asthma to assess the therapeutic effect of co-dergocrine ('Hydergine'), an alpha-adrenergic receptor blocking agent, when added to their standard treatment with a beta-adrenergic receptor stimulant and aminophylline. Co-dergocrine administration (3 to 6 mg per day) brought about marked improvement in 25% and an improvement in 55% of the patients. The results suggest that co-dergocrine could be a useful drug when combined with other bronchodilators in the treatment of bronchial asthma.

Topics: Adult; Aged; Asthma; Bronchodilator Agents; Dihydroergotoxine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged

1980